Lasa Supergenerics Ltd
NSE: LASA BSE: 540702
₹8.93
(0.22%)
Fri, 13 Feb 2026, 06:19 pm
Market Cap436.88M
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KLasa Supergenerics Analysis
dividend
- Unable to evaluate Lasa Supergenerics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Lasa Supergenerics's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Lasa Supergenerics is profitable, therefore cash runway is not a concern.
- Lasa Supergenerics is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (28.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.6x debt.
- Lasa Supergenerics's cash and other short term assets cover its long term commitments.
- Lasa Supergenerics's level of debt (34.2%) compared to net worth is satisfactory (less than 40%).
- Lasa Supergenerics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Interest payments on debt are not well covered by earnings (EBIT is 1.9x annual interest expense, ideally 3x coverage).
- High level of physical assets or inventory.
management
- The tenure for the Lasa Supergenerics board of directors is about average.
- Omkar's remuneration is about average for companies of similar size in India.
- Omkar's compensation has increased in line with Lasa Supergenerics recently becoming profitable.
misc
- Lasa Supergenerics is not covered by any analysts.
- Lasa Supergenerics has significant price volatility in the past 3 months.
past
- Lasa Supergenerics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- Lasa Supergenerics used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Lasa Supergenerics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Lasa Supergenerics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Lasa Supergenerics has become profitable in the last year making it difficult to compare the IN Pharmaceuticals industry average.
value
- Lasa Supergenerics is good value based on assets compared to the IN Pharmaceuticals industry average.
- 540702 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 540702 outperformed the Market in India which returned -14.5% over the past year.
- BSE:540702 is up 21.1% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:540702 is up 21.1% outperforming the market in India which returned 8% over the past month.
- Lasa Supergenerics is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Lasa Supergenerics is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800